Background Altered expression of specific microRNAs (miRNA) is known to occur during colorectal carcinogenesis. However, little is known about the genome-wide alterations in miRNA expression during the neoplastic progression of primary colorectal cancers. Methods Using a miRNA array platform, we evaluated the expression of 668 miRNA in primary colonic adenocarcinomas. Biological functions of selected miRNA were evaluated with in vitro invasion assays. Results RNA was extracted for miRNA analysis from 65 primary colon cancers. We identified a seven-miRNA expression signature that differentiated stage I and stage IV primary colon cancers. We then demonstrated this signature was able to discriminate between stage II and III primary colon cancers. Six differentially expressed miRNA were downregulated in association with the development of metastases, and all 7 miRNA were complementary strand miRNA. We transfected HCT-116, a highly invasive colon cancer cell line, with corresponding downregulated miRNA and demonstrated that overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential. Conclusion We have identified a seven-miRNA signature that is associated with metastatic potential in the primary tumor. Forced overexpression of three downregulated miRNA resulted in attenuation of in vitro invasion, suggesting direct tumor suppressive function and further supporting the biological importance of complementary strand miRNA.
Introduction
Colorectal cancer is the second most common cause of cancer mortality in Western societies, accounting for approximately 51,000 deaths yearly in the United States alone. 1 The vast majority of these deaths are secondary to the sequelae of metastatic disease, which is reflected in current staging algorithms. For example, the presence of lymphatic metastases (AJCC stage III disease) or distant metastases (AJCC stage IV disease) corresponds to an anticipated 5-year survival rate of 66% and 10% respectively, as compared to 90% for patients with early stage cancers. Although the association between mortality and metastases is clear, the genomic mechanisms underlying tumor cell dissemination and the acquisition of metastatic potential remain poorly understood. However, cellular regulation of a relatively new class of small RNAs, termed microRNAs (miRNA), may play an integral role in this malignant process. [2] [3] [4] [5] [6] miRNA are small (∼22 bp) endogenous RNAs that are known to serve important regulatory functions in many cellular processes including development, differentiation, proliferation, and cell death. 7 miRNA are initially transcribed by RNA polymerase and processed in the nucleus by DROSHA to form a pre-miRNA, which consists of a hairpin loop of RNA containing the miRNA and a complementary miRNA (denoted with asterisk). Following nuclear export, pre-miRNA are processed by DICER to yield both the mature miRNA and a mature complementary strand miRNA* (the latter of which was until recently [8] [9] [10] thought to be degraded as a non-functional by-product of miRNA metabolism secondary to decreased stability). miRNA are subsequently loaded into the RISC complex, where they are then able to alter the cellular transcriptome through translational inhibition and/or mRNA degradation.
A single miRNA can regulate hundreds of genes, and it has been estimated that 30% of all genes are regulated by miRNA. Given that differential regulation of a single miRNA can have broad cellular consequences, miRNA have been postulated to potentially serve as a superior class of cancer biomarkers; prognostic gene signatures may be created with relatively small numbers.
11 Additionally, several miRNA have previously been demonstrated to play regulatory roles in mediating colorectal cancer cell metastases. 12 Nonetheless, few studies have utilized comprehensive miRNA profiling to study colorectal cancer. We sought to evaluate miRNA expression in colon cancer across the spectrum of disease, focusing on the identification and evaluation of miRNA that may serve both predictive and functional roles during metastatic progression.
Methods

Tissue Samples
Tissues from patients undergoing surgical resection for colorectal cancer were collected with IRB approval and stored in the Tissue Procurement Core. Histopathological examination of resected specimens (histological type, tumor size etc.) was performed by an experienced GI pathologist (D.C.). A representative section of tissue was cut and stained with hematoxylin and eosin to confirm the diagnosis. Macrodissection of formalin fixed paraffin-embedded tissues was performed to isolate tumor sections (containing >90% tumor cells) for RNA extraction. Tumors that occurred in the background of genetic cancer syndromes or in the presence of inflammatory bowel disease were excluded.
MicroRNA Isolation and Labeling
Total RNA was isolated using the mirVANA™ miRNA Isolation Kit (Ambion Inc.) according to the manufacturer's protocol, including enrichment for small RNAs. RNA concentration and quality was determined using NanoDrop1000 (Thermo Fisher Scientific). Only RNA samples of sufficient quality were used. MicroRNA expression profiling was performed utilizing the TaqMan® Array Human MicroRNA Panel v1.0 (Early Access) (Applied Biosystems), a microfluidic card that Fig. 1 Algorithm for generation and evaluation of a metastasesassociated miRNA signature. We utilized prediction analysis for microarray (PAM) to compare primary stage I and stage IV colon cancers and generate a metastases-associated miRNA signature. We then utilized the signature to compare stage II and stage III primary colon cancers and utilized principal component analysis (PCA) to evaluate individual miRNA. Finally, we evaluated the in vitro phenotypic effects of overexpression of each miRNA contains 668 miRNA assays and five small nuclear RNAs (snRNA) that function as endogenous controls for data normalization. Single-stranded cDNA was synthesized from 200 ng of total RNA in eight Multiplex RT primer pool reactions containing stem-looped RT primers that were only specific to the mature miRNA. Quantitative PCR was carried out under the following thermocycler conditions, 30 min at 16°C, 30 min at 42°C, 5 min at 85°C and then held at 4°C. The resulting eight cDNA samples were diluted, combined with TaqMan Universal PCR Master Mix (Applied Biosystems), and then loaded onto a TaqMan Low Density MicroArray Panel, allowing for the simultaneous quantification of all 668 human miRNAs and five endogenous controls.
Statistical Analysis
miRNA Signature Development Our overall algorithm for generation and evaluation of a miRNA signature is shown in Fig. 1 . Prediction analysis for microarrays 13 (PAM) was used to compare AJCC stage I versus stage IV primary colon cancer and build a miRNA signature. Cross-validation was used to evaluate performance of prediction error rate. A miRNA set with the smallest overall error rate was selected as our miRNA signature. False discovery rate (FDR) was controlled at 1%.
Derivation of miRNA Signature In accordance with our previously published work, 14 our miRNA signature was generated using the first principal component to represent the overall expression level for our miRNA signature. The miRNA signature was then applied in discriminating AJCC stage II versus stage III primary colon cancers.
Data Normalization Raw Ct values above 32 were considered undetectable (i.e., no expression). RNU44 was used as the endogenous control gene to calculate average delta-Ct. DeltaCt values were converted to the log scale by subtraction of the maximum of delta-Ct value to each delta-Ct value (i.e., miRNA expression value0maximum (delta-Ct)−delta-Ct). The converted miRNA expression value was used for statistical analysis (data are available in GSE29622).
Evaluation of Histopathologic Association
We assessed the prognostic potential of the miRNA signature by examining its association with tumor grade/stage using the Pearson correlation and with overall survival using log-rank test based on the median cutoff.
Cell Culture and Transfection
HCT-116 cells were maintained in RPMI medium 1640 supplemented with 10% FBS, 1% penicillin-streptomycin, 1% L-glutamine, in a humidified incubator containing 5% CO 2 at 37°C. Twenty-four hours prior to transfection, HCT-116 cells were seeded in 6-well plates at 2×10 5 cells per well and incubated overnight at 37°C. Transfection was performed with Lipofectamine-2000 (Invitrogen) and 50 ng/well of pre-miRNA for the following miRNA: miR200c*, −15b*, −424*, −143*, −378*, −106b*, and negative control (Applied Biosystems), according to the manufacturer's protocol.
Quantitative Real-Time PCR Successful pre-miRNA transfection and subsequent miRNA overexpression in HCT-116 was confirmed using quantitative real-time PCR. Briefly, reverse transcription was carried out with TaqMan MicroRNA Assay Kit (Applied Biosystems) using miRNA*-specific primers. Quantitative real-time PCR for our miRNA and an endogenous control, RNU44, was performed using TaqMan Universal PCR Master Mix on a 7500 Fast Real-Time PCR System according to the manufacturer's protocol. miRNA expression levels were quantified and relative miRNA expression was calculated by comparative cycle threshold method (2 −ΔΔCT method), with RNU44 as the endogenous control.
Invasion Assay
Invasive potential was measured by the cells' ability to compromise an extracellular matrix in the presence of a chemoattractant using ECM pre-coated transwell membrane inserts (CytoSelect™ 24-well Cell Invasion Assay, Cell Biolabs Inc).
HCT-116 cells were harvested 48 h after transfection and transferred to serum-free RPMI medium. Cell suspension was added to the upper chamber, and the lower chamber was filled with 10% FBS which functioned as a chemoattractant. Following 24 h incubation at 37°C, non-migrated cells were removed with cotton swabs. Cells that invaded the lower surface of the membrane were stained with DAPI (Thermo Scientific), and counted per 100 high-power fields with an inverted microscope. All experiments were run in duplicate and performed on two separate occasions.
Results
Clinicopathologic Data
Primary tumor specimens from 65 patients with colon cancer (40 male, 25 female) of mean age of 65±13 years were evaluated. Tumor-specific pathologic data are depicted in Table 1 .
Differentially Expressed miRNA
A total of seven miRNA demonstrated significant differential expression between primary AJCC stage I tumors and primary stage IV tumors using PAM at threshold of 2.5 and controlling the FDR to <1%. The overall error rate was 8% by crossvalidation. Decreased expression was observed for six miRNA, while overexpression was observed for a single miRNA in comparing primary AJCC stage I and IV tumors ( Table 2 ). The aggregate miRNA signature was able to significantly differentiate between primary AJCC stage I and IV tumors (p00.0002; Table 2 ). The aggregate miRNA signature was also able to significantly differentiate between primary AJCC stage II and III tumors (p00.008; Table 2 ). In evaluating each miRNA individually in primary AJCC stage II tumors versus primary stage III tumors, three miRNA demonstrated significantly decreased expression (Table 2) . Of note, the miRNA signature was unable to differentiate AJCC stage I and stage II primary tumors (neither of which are associated with metastases) or AJCC stage III and stage IV primary tumors (associated with lymph node and distant metastases, respectively). Interestingly, we also evaluated each corresponding non-complementary miRNA of each miRNA* in our signature and found no similar correlations. We also failed to identify any consistent relationship between the level of expression of any individual miRNA* in our signature and its corresponding non-complementary miRNA ( Fig. 2 ) (i.e., overexpression of miRNA* was not consistently associated with co-overexpression or downregulation of the corresponding miRNA).
miRNA Signature and Tumor Grade Correlation
As expected, given our use of stage to derive differentially expressed miRNA, our miRNA signature showed association with overall survival. Interestingly, however, our miRNA signature was associated with decreasing tumor differentiation from well to poorly differentiated (r0−0.38 with p00.002; Table 3 , Fig. 3 ). The Pearson correlation was −0.67 (p< 0.0001) when the grade/stage were ranked from welldifferentiated of stage I to poorly-differentiated of stage IV. 
Tumor Given that 6 of the 7 miRNA in our signature were downregulated with tumor metastases, we sought to evaluate their ability to abrogate in vitro invasion through forced overexpression. We measured the endogenous expression of these 6 miRNA in HCT-116, a highly invasive colon cancer cell line, and found negligibly low expression for each miRNA (Ct value range 32-38). Prior to evaluation of invasive potential, we confirmed successful transfection with qRT-PCR for each miRNA of interest. After transfection, the mean expression Ct value was 17 (range 16.5-17.5) (Fig. 4) . Invasion was significantly suppressed with the overexpression of three miRNA; miR-200c*, miR-143*, and miR-424* (Fig. 4) as compared to cells transfected with the negative miRNA control. Additionally, we simultaneously overexpressed these three miRNA (miR-200c*, miR-143*, and miR-424*) and demonstrated the greatest degree of abrogation of metastatic potential, greater than that seen with the overexpression of any single miRNA* (Fig. 4) .
Discussion
Although the molecular alterations leading to tumor cell acquisition of metastatic capability remain unknown, miRNA have been reported to play an integral role through their ability to alter the transcriptome. We therefore evaluated the expression of 668 miRNA in primary colon cancers across the spectrum of stages using high-throughput miRNA technology. We identified a seven-miRNA signature, composed entirely of complementary strands, which correlated with tumor metastases. Interestingly, six of the seven miRNAwere downregulated with AJCC stage progression, suggesting tumor suppressor function. Additionally, forced overexpression of three miRNA resulted in attenuation of in vitro invasion, providing further evidence of direct tumor suppressive function, and supporting the biologic importance of complementary strand miRNA. Prior to fulfilling their regulatory roles through association with argonaute (AGO) proteins, miRNA exist in a miRNA: miRNA* duplex. Although the ultimate fate of the miRNA* strand was thought to be linked to the sorting pathways that act on their partner miRNA, such that loading of the two strands was inextricably linked in a ying-yang fashion, recent evidence suggests otherwise. In Drosophila, miRNA* species require canonical RNAi factors for their accumulation similar to endogenous siRNA and ultimately associate with AGO2, whereas miRNA associate with AGO1 through thermodynamic asymmetry. 10 Similarly, Ghildiyal et al. 9 demonstrated that loading of miRNA* in AGO2 is dependent on a unique combination of canonical miRNA and siRNA factors in Fig. 2 Relationship between complementary strand miRNA* and corresponding non-complementary strand miRNA. We failed to identify any relationship between the miRNA of interest and their corresponding non-complementary miRNA Drosophila. These data indicate independent regulation of partner miRNA:miRNA*, unveiling a new layer of complexity in miRNA metabolism. We found no relationship between the measurable expression of our seven miRNA* and their partner miRNA, which is similarly suggestive of independent mechanisms of regulation for miRNA and miRNA* in higher organisms.
The traditional view of tumor metastases involving a stepwise accumulation of advantageous mutations is changing. The importance of epigenetic regulation, and in particular alterations in miRNA expression, has come to the forefront of metastases research. [15] [16] [17] [18] Prerequisite accumulation of multiple genetic changes has been obviated by data demonstrating that multiple phenotypes can be acquired through a single alteration. For example, differential regulation of a single miRNA, miR-31, has been shown to modulate multiple phenotypes including motility and invasion in breast cancer cells. 19 Similarly, we have identified a panel-metastases-associated miRNA in colonic tumors and demonstrated the ability of a subset of the panel to abrogate in vitro invasion in colon cancer cells. Our panel is however composed entirely of miRNA*, which have only recently been demonstrated to play a functional role in tumor biology. miRNA* have demonstrated in vitro tumor suppressive regulation of important oncogenic genes. Tsang and Kwok, through forced overexpression and repression using multiple cancer cell lines, have shown that miR-18a* negatively regulates k-ras, with a demonstrable impact upon cell proliferation and anchorage-independent growth. 20 . Kim et al. 21 similarly demonstrated the pro-apoptotic effects of miR-199a* through forced overexpression in fibroblasts as a direct result of downregulation of the MET proto-oncogene and its downstream effector ERK2. miRNA overexpression experiments, however, need to be interpreted with caution. Competition is known to exist among small RNA for argonaute protection and saturation of argonaute binding capacity though introduction of exogenous miRNA has been shown to limit the function and stability of endogenous miRNA with unexpected but profound biological consequences. [22] [23] [24] [25] [26] Although we have not yet identified the gene targets of miR200c*, miR143*, or miR424*, it is important to note that the phenotypic changes observed with forced overexpression are not simply a consequence of miRNA regulatory perturbation; we utilized identical transfection conditions as well as pre-miRNA concentrations for all experiments and identified biological significance with overexpression of three of six downregulated miRNA.
Curiously, miR200c has been widely associated with development of the epithelial-to-mesenchymal transition (EMT) phenotype, which is characterized by an invasive tumor cell with metastatic potential, drug resistance, and stem cell-like properties. [27] [28] [29] [30] [31] [32] We have recently demonstrated that an EMT signature is intrinsic to a large population of human colorectal cancers and that this signature is closely linked to the expression of miR200c and its inhibition of ZEB1 and ZEB2. 33 Here, we report the intriguing result that the complementary strand miR200c* is associated with poor prognosis and metastatic development, and therefore may also be linked to the now recognized phenotype of EMT.
In addition to in vitro functional studies, miRNA* have recently been evaluated in patient tumor samples. Liu et al. 34 identified miR-23b* overexpression in 70% of renal cell carcinoma samples as compared to corresponding normal kidney, with a concomitant reduction in protein expression of the novel tumor suppressor proline oxidase. Jazdzewski et al. 35 demonstrated that a SNP in pre-miR146a led to the generation of two distinct complementary strand miRNA, miR-146a*G and miR-146a*C, which had a profound impact upon host cell transcriptomes and led to a predisposition toward the development of papillary thyroid carcinoma. Additionally, Schulte 36 identified differential expression of several miRNA* when comparing favorable versus unfavorable neuroblastomas. We identified the differential regulation of seven miRNA* in primary colon cancers, none of which have been previously reported, although clearly, the evaluation of complementary strand miRNA is in its infancy. In addition to our results and those reported in renal, thyroid, and neural malignancies, a comprehensive bioinformatic and microarray analysis has shown that miRNA* impact vertebrate regulatory networks and likely play significant roles during oncogenesis, 37 which in aggregate may serve as a catalyst for increasing investigation of the role of miRNA* in various cancers.
We derived a metastatic miRNA signature from primary non-metastatic colon cancers under the premise that progressive identifiable alterations in miRNA expression occur until such a time that a threshold is reached, prompting acute acquisition of metastatic capability and cellular dissemination from the primary tumor. We believe this threshold is breached by a minority population of cells within the primary tumor, although some degree of progression toward the threshold is reflected in the bulk of the tumor mass. If conceptualized in the context of an epithelial-to-mesenchymal transition (EMT)-like process, we have potentially identified a panel of synergistic pro-epithelial miRNA whose expression levels inversely correlate with tumor dedifferentiation (Fig. 3) and metastatic potential. Our signature may therefore be useful in stratifying early stage (AJCC I and II) primary colon cancers for the potential of associated occult metastatic disease and thereby identification of patients that may benefit from early aggressive adjuvant therapy.
Discussant
Yun Shin Chun (Philadelphia, PA): Dr. Hernandez, congratulations on this important contribution to our understanding of molecular changes in colon cancer. Since one microRNA (miRNA) regulates expression of hundreds of genes, much information can be gathered from analysis of over 600 miRNAs as you have shown. The seven miRNA signature significantly discriminates between stage I and IV colon cancer patients and between stage II and III, although there is no difference between stage III and IV patients. Six of the seven miRNAs are downregulated, consistent with published literature showing a general downregulation of miRNAs in cancer cells compared to nontumorous tissue, indicating a tumor suppressor effect of many miRNAs. Notably, all of the seven miRNAs in this signature are complementary strand miRNAs, which were previously thought to be biologically inactive. There was no correlation between levels of complementary strand and mature miRNAs, suggesting a biologic function of complementary strand miRNAs distinct from their corresponding mature miRNAs.
I had three questions: 1. What are the differential levels of miRNAs in primary colon cancers compared with nodal and systemic metastases, and what are the changes in expression levels with preoperative chemotherapy?
2. Second, miR-21 is perhaps the most studied dysregulated miRNA in colon cancer. What were the expression levels of miR-21 in your patients?
3. Third, can you speculate on practical diagnostic or therapeutic applications of your findings?
Closing Discussant
Dr. Jonathan Hernandez: Regarding your first question, we have not evaluated the effect of neoadjuvant chemotherapy on the expression of miRNA. We have also not specifically evaluated miRNA expression in either lymph node or systemic metastases, although this would be of significant interest. If one accepts that lymph node metastases represent in-transit cells similar to circulating tumor cells, we would expect low or negligible expression of miRNA that inhibit genes associated with the acquisition of metastatic potential. According to our data, miR200c*, miR143*, and miR424* may be examples of such miRNA. If conceptualized in the context of epithelial-to-mesenchymal transition (EMT), we would predict that systemic macrometastases display miRNA expression profiles similar to primary tumors given that mobile mesenchymal cells undergo an epithelial transition in order to recapitulate a tumor mass.
To answer your second question, miR-21 has been shown to target PTEN, and thereby deregulate the PI3K pathway, increasing AKT signaling. We found no differential expression of miR-21 across the spectrum of AJCC stage I-IV primary colon cancers. We definitely observed expression of miR-21, although I'm not sure the absolute value is meaningful in terms of external comparison.
Finally, in response to your third question, our signature may have prognostic value in discriminating those patients with apparent early-stage tumors that eventually develop overt metastatic disease. We may be able to determine a metastatic probability for these patients based upon the expression of metastases-associated miRNA in the primary tumor. Firstly, such a signature may allow the identification of patients with early stage disease who may benefit from the use of adjuvant chemotherapy. Secondly, we believe that the therapeutic application as it relates to the individual miRNAs will be predicated upon elucidation of the functional biology of each miRNA in our signature. In this latter case, however, anti-miR therapy is currently in its infancy and may not have immediate direct translational applicability.
